Detalhe da pesquisa
1.
Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.
Oncologist;
2024 Jun 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38828490
2.
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Oncologist;
2024 Jun 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38837045
3.
Brief Report: Improving Fellow Performance of the Pharmacology Section of the American Society of Clinical Oncology In-Training Exam.
J Cancer Educ;
38(1): 141-145, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34535877
4.
Seeking Racial Equity in Hematology and Oncology: a Fellow-Led Educational Series to Promote Reflection and Action.
J Cancer Educ;
38(4): 1241-1244, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36598746
5.
Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer.
Oncologist;
27(12): 1006-e930, 2022 12 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36288238
6.
Clinical and Histological Response to Talimogene Laherparepvec Therapy in Advanced Melanoma: Impact on Overall Survival.
J Am Coll Surg;
238(4): 508-516, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38224076
7.
Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity.
J Immunother;
44(3): 127-131, 2021 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32925564